• BMN 673 (Talazoparib): Evidence and Research Context

  2026-10-06

  BMN 673, also known as Talazoparib, is a PARP1/2 inhibitor studied in the context of DNA repair deficiency and PARP-DNA complex trapping. This overview distinguishes vendor-reported biochemical and preclinical claims from findings in a 2024 hepatocellular carcinoma study, which examined SmD2, alternative splicing, BRCA1/FANC expression, and sensitivity to PARP inhibition. The evidence supports a research framework linking spliceosome regulation with homologous recombination deficiency, but it does not directly establish Talazoparib activity in the reported HCC models. Key limitations include model dependence, incomplete comparative data, and the gap between mechanistic rationale and clinical applicability.

• Bifidobacterium, FMT, and PET in Hepatic Encephalopathy

  2026-10-06

  A 2025 European Journal of Neuroscience study compared Bifidobacterium and fecal microbiota transplantation in rats with chronic hepatic encephalopathy using [18F]PBR146 micro-PET/CT imaging. The work’s main contribution is a region-sensitive, noninvasive framework for evaluating gut-targeted interventions, while its mixed behavioral, cytokine, imaging, and microbiome findings emphasize the limits of treating PET signal as a standalone measure of therapeutic benefit.

• Bobcat339 and DNA Methylation: A TET Lens

  2026-10-05

  Bobcat339 is a cytosine structure-based TET enzyme inhibitor for investigating DNA methylation regulation and gene transcription modulation. This article places the compound alongside a 2026 osteoporosis study to clarify what chemical TET perturbation can—and cannot—reveal about enhancer remodeling and osteogenic dysfunction.

• CKI 7 Dihydrochloride: Evidence and Research Context

  2026-10-05

  This overview places CKI 7 dihydrochloride in context as a research tool for studying Casein kinase 1 biology, while separating supplier claims from peer-reviewed evidence. It also examines the supplied MAPK10–KRT16–RNF213 study in NSCLC and explains why its findings do not, by themselves, establish a role for CK1 inhibition in lung-cancer metastasis.

• How Neuroligin 1 Supports Social Memory

  2026-10-04

  The 2025 study identifies a proteolytic Neuroligin 1 fragment, NLG1-CTD, as a regulator of social-memory maintenance in the mouse ventral hippocampus. Its evidence connects social experience, secretase-dependent signaling, cofilin regulation, and dendritic-spine remodeling, while also defining important boundaries for translation beyond the experimental model.

• Moret et al. on Data-Driven Small-Molecule Libraries

  2026-10-03

  Moret et al. introduced a data-driven framework for comparing and designing focused small-molecule collections using selectivity, target coverage, cellular phenotypes, chemical structure, clinical status, and user-defined priorities. Their analysis showed that optimized libraries can improve target coverage while reducing redundancy, with implications for chemical genetics, mechanism-of-action studies, and cancer biology research.

• BMN 673: PARP Trapping Meets Spliceosome Biology

  2026-10-02

  BMN 673 (Talazoparib) combines exceptionally potent PARP1/2 inhibition with strong PARP-DNA complex trapping. This article develops a biomarker-led research framework connecting talazoparib response to spliceosome regulation, BRCA1/FANC isoforms, and DNA repair deficiency.

• Patient-Derived Gastric Cancer Assembloids

  2026-10-01

  The reference study develops patient-specific gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal subpopulations. Its findings show that stromal composition alters gene expression and drug sensitivity, creating a more informative model for tumor–microenvironment research and personalized treatment studies.

• RepSox for iPSC Differentiation Workflows

  2026-09-30

  RepSox provides a selective ALK5 inhibition arm for studying TGF-β control of reprogramming, differentiation, and megakaryocyte maturation. This practical guide connects product handling with an optimized hiPSC-to-platelet workflow while separating published benchmarks from conditions that require local validation.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma

  2026-09-30

  A dCas9-based transcriptional screen identified structurally diverse histone deacetylase inhibitors as repressors of BRD4-NUT activity in NUT carcinoma. The study links HDAC inhibition to loss of megadomain-associated oncogene expression, induction of differentiation programs, and improved tumor control when combined with bromodomain inhibition.

• Sulfo-NHS-SS-Biotin: Practical Labeling Guide

  2026-09-29

  Sulfo-NHS-SS-Biotin is a water-compatible, amine-reactive reagent for labeling lysine side chains and N-terminal amines before avidin/streptavidin affinity chromatography. Its disulfide spacer permits reduction-based release of the biotin label, while its sulfo-NHS ester requires fresh preparation and immediate use. It is appropriate for surface-accessible or purified proteins, but not for intact-cell intracellular labeling without a separate permeabilization strategy.

• Dasatinib: A Mechanistic Assay Design Guide

  2026-09-29

  Dasatinib and BMS-354825 are powerful tools for separating proximal kinase effects from complex cancer phenotypes. This guide develops a causal assay framework linking Src, Bcr-Abl, FAK phosphorylation, EMT, and the SNAI1–PIK3R2/p-EphA2 axis.

• RBMS1 Loss Enables PD-L1 Blockade in TNBC

  2026-09-28

  A 2022 study identified the RNA-binding protein RBMS1 as a post-transcriptional regulator of PD-L1 stability in immune-cold triple-negative breast cancer. By linking RBMS1 depletion to reduced B4GALT1 expression, impaired PD-L1 glycosylation, and stronger cytotoxic T-cell activity, the work provides a mechanistic rationale for improving checkpoint-based and CAR-T strategies.

• Beyond D2: A Translational Strategy for Trifluoperazine 2HCl

  2026-09-28

  A mechanistic and translational framework for using Trifluoperazine 2HCl to study dopamine D2 receptor signaling while separating target-linked effects from broader cellular responses.

• RRP Restores Lipid Balance in Hepatic Ischemia-Reperfusion

  2026-09-27

  This study links Radix Rehmanniae Praeparata (RRP) protection against hepatic ischemia-reperfusion injury to coordinated changes in cholesterol synthesis and efflux. In mouse and hepatocyte models, RRP activated AMPK-associated signaling, restrained SREBP2 processing, and promoted LXRα activity, providing a mechanistic framework for investigating lipid dysregulation in liver injury.

7973 records 1/532 page Next 12345 下5页 Last page